Compare DexCom, Inc. (DXCM) vs Unilever plc (UL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Unilever plc — how do they compare? DexCom, Inc. trades at $88.22 (market cap $33.08B), while Unilever plc trades at $62.32 (market cap $134.76B). The key difference: Unilever plc is far larger — about 4.1× DexCom, Inc.'s market cap, and Unilever plc pays a 3.63% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | UL | |
|---|---|---|
Market Cap | $33.08B | $134.76B |
Sector | Health | Consumer Staples |
52-Week High | $89.53 | $74.59 |
52-Week Low | $54.84 | $55.05 |
Enterprise Value | $32.53B | $160.58B |
Dividend Yield | — | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.75, up 2.08% today and near its 52-week high. The stock shows bullish technical momentum with strong earnings beats in recent quarters, including Q2 2026 EPS of $0.70 versus $0.61 expected. Revenue growth accelerated to 13% year-over-year in Q2 2026, driven by G7 system adoption and international expansion. Cash flow from operations improved to $1.44 billion in 2025, supporting financial flexibility.
Outlook remains positive with raised FY2026 guidance and 80% analyst buy ratings, though valuation multiples like P/E of 33.5 suggest premium pricing. Key risks include competitive pressures in glucose monitoring and reliance on reimbursement policies. The consensus price target of $88.65 implies modest upside from current levels.
Unilever (UL) trades at $62.96, down 1.1% over 24 hours, with technical indicators showing a bullish trend and strong support at $62. The company reported $50.5B revenue in 2025 with a net income margin of 18.75%, though recent quarters saw earnings misses. Positive sentiment is driven by a potential merger with McCormick and strong Q2 2026 volume growth, while analyst consensus is mixed with 24% buy ratings.
The outlook is cautiously optimistic due to merger synergies and margin expansion potential, but risks include integration challenges and competitive pressures. Cash flow volatility and debt levels warrant monitoring. The stock presents a value opportunity if execution improves, but near-term volatility may persist amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Unilever plc
Unilever is a diversified personal product (42% of 2021 sales by value), home care (20%), and packaged food (38%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Lipton teas, Axe and Dove skin products, and the TRESemme haircare brand. The firm has been acquisitive in recent years
Read more on UL →
